Evidence map›Paper›PMID 42403013›Full record

ArticleBrain : a journal of neurology2026

Fus-depleted oligodendrocytes reduce neuronal damage and Alzheimer's disease progression in the AppNL-G-F mouse.

Te-Hsuan Tung, Sudhagar Babu, Xiangting Tang, Alec L Sciutto, Micah Romer, Prathima Racha, Rong Xu, Victoria Fiesler, Adrita Saha, Teresa Thai and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Brain : a journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Update of
    2025
5 · Who and what money

Authors and funding

17 authors.

Te-Hsuan TungPittsburgh Institute for Neurodegenerative Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15206, USA.ORCID 0000-0002-0712-4861
Sudhagar BabuDepartment of Neurobiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15206, USA.ORCID 0000-0001-6012-8936
Xiangting TangPittsburgh Institute for Neurodegenerative Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15206, USA.
Alec L SciuttoPittsburgh Institute for Neurodegenerative Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15206, USA.
Micah RomerChildren Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Prathima RachaPittsburgh Institute for Neurodegenerative Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15206, USA.
Rong XuDepartment of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA,15213  USA.
Victoria FieslerPittsburgh Institute for Neurodegenerative Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15206, USA.
Adrita SahaDepartment of Neurobiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15206, USA.ORCID 0009-0003-7686-1712
Teresa ThaiDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Takashi SaitoDepartment of Neurocognitive Science, Institute of Brain Science, Nagoya City University, Nagoya, Aichi, 467-8601, Japan.
Takaomi C SaidoRIKEN Brain Science Institute, Wako, Saitama, 351-0198, Japan.
Yongxin ZhaoDepartment of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA,15213  USA.
Judith B GrinspanChildren Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Hansruedi MathysDepartment of Neurobiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15206, USA.
Takashi D Y KozaiDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Franca CambiPittsburgh Institute for Neurodegenerative Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15206, USA.ORCID 0000-0002-3094-1501

Funding

Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorderR01MH098742 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI JUDITH B GRINSPAN, Kelly L Jordan-Sciutto · 2012 to 2026
$9.0M
Effects of HIV and ART on myelination in the adolescentR01MH126773 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GRINSPAN, JUDITH B, JORDAN-SCIUTTO, KELLY L · 2021 to 2025
$3.9M
Using Electrical Stimulation to Modulation Microglia and the Conversion of Microglia PhenotypesR01NS115707 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KOZAI, TAKASHI DANIEL YOSHIDA · 2020 to 2024
$3.2M
Subcellular Wireless Axons for in vivo Localized Neuronal ExcitationR01NS105691 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Takashi Daniel Yoshida Kozai, Wen Li · 2020 to 2026
$3.1M
Mechanisms of Oligodendrocyte Activity on Chronic Brain Implants and Recording PerformanceR01NS129632 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRANCA CAMBI, Takashi Daniel Yoshida Kozai · 2023 to 2026
$2.4M
Cognitive decline in aging and AD: neuroprotection by hypermyelination in FusOLcKOR03AG072218 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CAMBI, FRANCA · 2022 to 2023
$309k
NIA NIH HHS R03 AG072218NIMH NIH HHS R01 MH098742NIMH NIH HHS R01 MH126773NINDS NIH HHS R01 NS105691NINDS NIH HHS R01 NS115707NINDS NIH HHS R01 NS129632
6 · The paper itself

Abstract

Alzheimer's Disease (AD) is an age-dependent neurodegenerative disorder and represents the most common type of dementia, increasing in incidence at an alarming rate in the aging population. The hallmarks of the disease are amyloid plaque accumulation, microglia and astrocyte activation, and loss of presynaptic structure leading to cognitive decline. Recently, oligodendrocyte (OL) and myelin abnormalities have emerged as important contributors to the pathogenesis of AD. In normal brain homeostatic conditions, OL maintain neuronal health through myelin axon interactions and by supplying neurotrophic and metabolic support. How strengthening OL function may support neuronal health in AD neurodegeneration remains to be fully characterized and represents a gap in knowledge and a missed therapeutic opportunity. This study sought to examine how myelin and OL may improve neuronal deficits associated with AD. We have generated a novel mouse model (AD/cKO) by crossing the AppNL-G-F mouse, an established AD model, which carries three human AD mutations in the mouse App gene, with the FusOLcKO whose OL depleted of Fus (Fused in Sarcoma) produce thicker myelin associated with greater cholesterol biosynthesis. We evaluated spatial memory function with standardized cognitive testing. We evaluated microglia density and state, astrocytic activation and toxic phenotype, myelin density, cholesterol content, amyloid plaque burden, presynaptic structures, and neuronal hypoxic and oxidative damage in the hippocampus and cortex. We characterized the transcriptome of AD/cKO hippocampal OL compared to AD by using single-cell transcriptomic studies. Spatial working memory was fully preserved in the aged AD/cKO mouse relative to the AD mouse. This outcome was associated with reduced neuronal oxidative damage, preserved presynaptic structures at the amyloid plaque niches, and a shift in microglia state at the niches in both hippocampus and cortex. In contrast, amyloid plaque burden and microglia density were decreased in the hippocampus but not in cortex, uncoupling the neuronal and microglia effects from the amyloid burden. Fus dependent myelin increase was present in both hippocampus and cortex. Single-cell transcriptomics of AD/cKO hippocampal OL revealed upregulation of energy metabolism and antioxidant genes, suggesting a role of OL enhanced energy metabolism in mediating protection of neurons and affecting microglia state in AD pathology. This work provides new insight into how oligodendrocytes may protect neurons in AD, communicate with other glial cellular players, and point to potential targets for disease intervention aimed at slowing AD progression.

Indexed as

lipid metabolismmicrogliamitochondrianeuroinflammationneuroprotectiontranscriptomics

Identifiers

PMID42403013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.